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spread rapidly around the world. Currently, al-
most the entire world is affected by the ongoing 
COVID-19 pandemic.1,2 It has been confirmed 
IntroductIon Coronavirus disease 2019 
(COVID-19) was first reported in Wuhan, Chi-




















Background Primary percutaneous coronary intervention (PPCI) as the treatment of choice for ST-segment 
elevation myocardial infarction (STEMI) should be rapidly performed. It is necessary to use preventive strategies 
during the coronavirus disease 2019 (COVID-19) outbreak, which is an ongoing global concern. However, critical 
times in STEMI management may be influenced by the implementation of infection control protocols.
aims We aimed to investigate the impact of our dedicated COVID-19 PPCI protocol on time components 
related to STEMI care and catheterization laboratory personnel safety. A subendpoint analysis to compare 
patient outcomes at a median time of 70 days during the pandemic with those of patients treated in 
the preceding year was another objective of our study.
methods Patients with STEMI who underwent PPCI were included in this study. Chest computed 
tomography (CT) and real-time reverse transcriptase–polymerase chain reaction (rRT-PCR) tests were 
performed in patients suspected of having COVID-19. A total of 178 patients admitted between February 29 
and April 30, 2020 were compared with 146 patients admitted between March 1 and April 30, 2019.
results Severe acute respiratory syndrome coronavirus 2 infection was confirmed by rRT-PCR in 7 cases. 
In 6 out of 7 patients, CT was indicative of COVID-19. There were no differences between the study groups 
regarding critical time intervals for reperfusion in STEMI. The 70-day mortality rate before and during 
the pandemic was 2.73% and 4.49%, respectively (P = 0.4).
conclusions The implementation of the dedicated COVID-19 PPCI protocol in patients with STEMI 
allowed us to achieve similar target times for reperfusion, short-term clinical outcomes, and staff safety 
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with STEMI, the current pandemic may have 
a negative impact on clinical outcomes.4,10 How-
ever, to the best of our knowledge, no study has 
reported the impact of the COVID-19 pandem-
ic on the outcomes of patients undergoing PPCI.
It is well known that PPCI for acute STEMI 
is a more effective revascularization method 
than thrombolytic therapy, if it can be swiftly 
performed (within 90 minutes) in capable cen-
ters.10 However, concerns regarding infection 
transmission from infected patients to the PPCI 
team have resulted in challenging recommen-
dations for choosing the reperfusion strategy 
in patients with acute STEMI.
The Tehran Heart Center (THC), as the major 
academic tertiary hospital specialized in car-
diovascular disorders in Iran, has been provid-
ing PPCI services 24 hours a day, 7 days a week 
since 2015. On average, 960 PPCI procedures are 
performed in THC every year. Infection control 
protocols against COVID-19 have been imple-
mented in this center since February 19, 2020.
In this study, we aimed to investigate the im-
pact of the COVID-19 outbreak on time compo-
nents related to STEMI management and assess 
the outcomes of the study patients at a median 
time of 70 days as a secondary endpoint.
Methods study participants All eligible 
patients who presented to the THC emergen-
cy department with acute STEMI between Feb-
ruary 29 to April 30, 2020 and underwent PPCI 
were enrolled in the study. Patients whose diag-
nosis were not compatible with STEMI on cor-
onary angiography were excluded from further 
analysis. In addition, patients who refused to 
undergo the procedure or in whom cardiac ar-
rest occurred before PPCI (n = 0) were not eli-
gible. Other exclusion criteria pertained to pa-
tients with an unclear onset time of angina 
symptoms (n = 0) and inpatient candidates (n = 
5). The ethics committee of THC and the insti-
tutional review board approved the study pro-
tocol (IR.TUMS.VCR.REC.1399.023).
Protocol In the THC emergency department, 
acute STEMI is diagnosed by a cardiology resi-
dent, based on the patient’s electrocardiogram. 
Then, an on-site interventional cardiologist is 
informed about the case by an immediate tele-
phone call. Then, the Heart Team including a car-
diology resident and an on-site intervention-
al cardiologist evaluate the patient’s eligibili-
ty for PPCI; the assessment includes but is not 
limited to severe comorbidities. If the patient 
is considered eligible for PPCI, the 24/7 code is 
activated without any further ado and the pa-
tient is being prepared for transfer to the cath-
eterization laboratory after obtaining their in-
formed consent. If necessary, the loading dose 
of aspirin, P2Y12 receptor inhibitors, statins, 
that coronavirus disease 2019 spreads by hu-
man-to-human transmission, even from 
an asymptomatic carrier, with a basic
 
repro-
ductive number best estimated at 2.2,2 which 
suggests that, on average, every case of COV-
ID-19 will generate 2 new cases. Since the dis-
ease is highly contagious and there is no specific 
treatment for it, prevention through infection 
control protocols is necessary and inevitable.2-4 
Hospitals and other medical centers are respon-
sible for adapting their inpatient and outpatient 
healthcare services for this critical condition.5
Acute ST-segment elevation myocardial in-
farction (STEMI) is the most severe presentation 
of coronary artery disease and results in consid-
erable morbidity and mortality. In order to min-
imize the myocardial infarct size and preserve 
the viability of the ischemic region, it is crucial 
to expedite treatment with early diagnosis and 
quick patient transfer to the catheterization 
laboratory for primary percutaneous coronary 
intervention (PPCI), which is a definitive treat-
ment method.6-8 However, there have been lim-
ited data regarding the impact of the COVID-19 
outbreak on the management and outcomes of 
patients undergoing PPCI.4,5,9
Scarce data available have shown that the 
COVID-19 outbreak might result in prolong-
ing ischemic time in patients with acute STEMI, 
probably due to: 1) the implementation of infec-
tion control protocols such as using full person-
al protective equipment (PPE) by the PPCI staff 
during the procedure; 2) asking about the his-
tory of travelling to affected regions and con-
tact with persons with suspected or confirmed 
COVID-19 as well as evaluating the symptoms of 
respiratory infection before transferring the pa-
tient to the catheterization laboratory; and 3) 
patients’ disinclination to go to the hospital dur-
ing the COVID-19 pandemic.4,5 Given that reper-
fusion delay decreases the survival of patients 
whAt’s new?
One of the major questions asked by cardiologists is “What is the preferred 
treatment in the management of acute ST-segment elevation myocardial 
infarction (STEMI) during the coronavirus disease 2019 (COVID-19) outbreak? 
Primary angioplasty or fibrinolytic therapy.” It is necessary to implement 
infection prevention protocols in hospitals. However, using full personal 
protective equipment by the medical staff may lead to STEMI-related time 
interval prolongation and affect patient outcomes. This study in Tehran Heart 
Center demonstrated unexpected trends towards reduced target times in the 
in-hospital pathway during 2 months amid the COVID-19 pandemic compared 
with the prepandemic era. It seems that limited elective invasive procedures 
during the disease outbreak resulted in reduced waiting time for the preparation 
of routinely occupied catheterization laboratories and diminishing the staff 
workload. Meanwhile, the 70-day outcomes including mortality and nonfatal 
major adverse cardiac event rates did not significantly differ as compared with 
the preceding year. Thus, we did not find it necessary to change the current 
STEMI protocols.
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center is presented in FIGURE 1. All patients are eval-
uated for signs and symptoms of severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection using a predefined checklist (TAblE 1). In 
patients suspected of having COVID-19, spiral 
chest computed tomography is performed after 
PPCI as well as nasal and oropharyngeal swab 
samples are collected for nucleic acid testing 
by real-time reverse transcriptase–polymerase 
chain reaction (rRT-PCR) using the (2019-nCoV) 
Triplex RT-qPCR Detection Kit (CE-IVD) (Nan-
jing Vazyme Medical Technology Co., Ltd., Nan-
jing, China). Unfortunately, due to shortage of 
RT-PCR kits, the “test-all” strategy was not fol-
lowed in all admitted patients.
Given that patients may be asymptomatic car-
riers of SARS-CoV-2, the entire catheterization 
laboratory staff who comes in close contact with 
the patient should wear appropriate PPE regard-
less of the patient’s signs and symptoms of respi-
ratory infection. Personal protective equipment 
and other drugs are administered in the emer-
gency department. The PPCI procedure is per-
formed if it is indicated according to the inter-
national guidelines.7,8 In line with the 2017 Eu-
ropean Society of Cardiology (ESC) guidelines,7 
all patients receive a maintenance dose of aspi-
rin and a P2Y12 receptor inhibitor (as dual an-
tiplatelet therapy) and lipid-lowering agents 
(high-dose statins) during the early phase of 
STEMI. Angiotensin-converting enzyme inhib-
itors are administered on admission in patients 
with reduced left ventricular systolic function 
(left ventricular ejection fraction <40%), ante-
rior STEMI, hypertension, and diabetes. An-
giotensin II receptor blockers are considered as 
an alternative in patients who are intolerant to 
angiotensin-converting enzyme inhibitors. All 
patients are treated with oral β-blockers, unless 
contraindicated.
The STEMI management strategy during the 
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 Figure 1 The Tehran Heart Center protocol for the management of ST-segment elevation myocardial infarction during the coronavirus disease 2019 pandemic
 a Any of the following: fever, dry cough, sore throat, myalgia, chills, oxygen saturation <93%, lymphopenia, thrombocytopenia
 b All patients should be transferred to the catheterization laboratory with an oxygen mask on.
 c Respiratory failure due to coronavirus disease 2019, septic shock, and poor lung prognosis
 Abbreviations: COVID-19, coronavirus disease 2019; CT, computed tomography; PCI, percutaneous coronary intervention; PCR, polymerase chain reaction; 
STEMI, ST-segment elevation myocardial infarction
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all-cause mortality, nonfatal MI, repeated re-
vascularization (PCI or coronary artery by-
pass grafting), cerebrovascular accidents, and 
rehospitalization.
statistical analysis We reported categori-
cal variables as number (percentage), and con-
tinuous variables, as mean (SD) and median 
(interquartile range) for those with and with-
out normal distribution, respectively. The Kol-
mogorov‒Smirnov test was used to assess the 
normality of distribution.
Differences between the study groups were 
analyzed using the  independent  t  test, the 
Mann–Whitney test, and the χ2 test for con-
tinuous (normally or non-normally distribut-
ed) and categorical variables, respectively. Sta-
tistical analysis was performed using the SPSS 
software, version 26 (IBM Corporation, Armonk, 
New York, United States). A P value less than 0.05 
was considered significant.
results A total of 178 patients with STEMI 
who underwent PPCI between February 29 and 
April 30, 2020 were compared with 146 patients 
with STEMI treated during the same time peri-
od in 2019. The demographic and clinical char-
acteristics of the study patients are presented 
in TAblE 2. There were no differences between the 
2 groups except for a significantly higher prev-
alence of hypertension among patients treat-
ed during the COVID-19 outbreak (52.24% vs 
40.41%; P = 0.04). Chest CT and rRT-PCR nucleic 
acid testing were performed in 33 patients who 
were suspected of having COVID-19, based on 
the checklist. Out of 21 cases with chest CT in-
dicative of COVID-19, the diagnosis was con-
firmed by rRT-PCR testing in 6 patients. Seri-
al chest CT scans in a single patient with suspi-
cious symptoms were unremarkable, but rRT-
PCR testing confirmed the infection.
Although no differences were observed be-
tween the 2 study groups in terms of STEMI-re-
lated target times, a trend towards a prolonged 
time from symptom onset to FMC (P = 0.84) 
and shorter time intervals from FMC to STEMI 
diagnosis (P = 0.16), from STEMI diagnosis to 
includes an isolated gown, disposable gloves, 
a face shield or goggles, and an N95 mask for 
each procedure. The healthcare personnel is eval-
uated daily and asked about their symptoms. 
Body temperature is routinely checked.
To determine the impact of the COVID-19 out-
break on STEMI care–related time frames and 
70-day outcomes in this patient population, we 
compared patients treated with PPCI for acute 
STEMI during the pandemic with those treat-
ed between March 1 and April 30, 2019 (n = 146) 
using the THC 24/7 registry. The same inclusion 
and exclusion criteria were applied in all patients. 
Due to the possibility of patients’ fear of leav-
ing home during the pandemic era, antiplate-
lets, statins, and antihypertensive agents were 
prescribed for at least 3 months at discharge. 
Both during and before the COVID-19 outbreak, 
oral anticoagulation was not indicated in any of 
the patients. To follow up the patients during 
the pandemic, trained nurses contacted them 
by phone at 1 month, 3 months, and 6 months 
after discharge, recorded their current symp-
toms, drug compliance, adherence to treatment, 
living status, and major adverse cardiac event 
(MACE) components, and informed cardiolo-
gists about any findings. Our follow-up clinics 
were also available for patients willing to visit 
their doctors in person.
Definitions We evaluated target times relat-
ed to STEMI care according to the 2017 ESC rec-
ommendations7 including time intervals from 
symptom onset to first medical contact (FMC), 
from FMC to STEMI diagnosis, from STEMI 
diagnosis to wire crossing, and from FMC to 
wire crossing.
First medical contact denoted the initial ex-
amination of the patient by a physician, a nurse, 
a paramedic, or another trained emergency med-
ical service staff member who could perform 
electrocardiography and interpret its results. 
The timepoint at which ST-segment elevation 
or equivalent was present on the electrocardio-
gram of a patient with ischemic symptoms was 
defined as the time of STEMI diagnosis.7
A 70-day MACE rate was evaluated as the out-
comes of patients with STEMI and defined as 
Table 1 Coronavirus disease 2019 screening checklist
Fever (>37.3 °C) Headache




Rhinorrhea or sneezing Ageusia
Abbreviations: see FIGURE 1
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in terms of 70-day occurrence of nonfatal MAC-
Es (P = 0.8) (TAblE 4). None of the catheterization 
laboratory personnel members presented with 
COVID-19–related symptoms until the end of 
the study period.
All patients with STEMI during the prepan-
demic era received and tolerated dual antiplate-
let therapy for 12 months. Follow-up showed 
that patients had no problems with access and 
adherence to medications during the pandemic.
One out of 7 patients with COVID-19 con-
firmed by rRT-PCR died during hospitalization. 
The patient was a 48-year-old man with a histo-
ry of diabetes, hypertension, and kidney trans-
plant performed 9 years earlier. He also received 
immunosuppressive drugs, smoked cigarettes, 
and abused opium. The patient presented with 
sore throat and weakness accompanied by typi-
cal chest pain. The time intervals from symptom 
wire crossing (P = 0.95), and from FMC to wire 
crossing (P = 0.12) were reported during the CO-
VID-19 outbreak compared with the same peri-
od in the preceding year (TAblE 3).
There was no significant difference between 
patients treated during the COVID-19 outbreak 
(8 patients [4.49%]) and those treated during 
the same period in the preceding year (4 patients 
[2.73%]) with respect to 70-day all-cause mor-
tality (P = 0.4). Single cases of nonfatal MI, re-
peated revascularization with coronary artery 
bypass grafting, and rehospitalization in the 
cardiac care unit were reported at a median fol-
low-up of 70 days in patients who were admitted 
in 2019. A single case of nonfatal MI and 2 read-
missions to the cardiac care unit occurred at fol-
low-up of the same duration in patients with 
STEMI during the COVID-19 outbreak. There 
was no difference between the 2 study groups 
Table 2 Demographic and clinical characteristics of the study patients with acute ST-segment elevation 
myocardial infarction who underwent primary coronary angioplasty during (February 29 to April 30, 2020) and 
before (March 1 to April 30, 2019) the coronavirus disease 2019 pandemic
Characteristics During the COVID-19 
outbreak (n = 178)
Before the COVID-19 
outbreak (n = 146)
P value
Age, y, mean (SD) 58.80 (12.18) 59.82 (11.03) 0.43
Sex Female 41 (23.03) 32 (21.91) 0.81
Male 137 (76.97) 114 (78.09)
Diabetes 81 (45.5) 65 (44.52) 0.89
Hypertension 93 (52.24) 59 (40.41) 0.04
Dyslipidemia 95 (53.37) 80 (54.79) 0.83
Cigarette smoker Current 64 (35.95) 56 (38.35) 0.47
Former 10 (5.61) 12 (8.21)
Opium consumption Current 18 (10.11) 16 (10.95) 0.87
Former 6 (3.37) 7 (4.79)
Family history of PCAD 45 (25.28) 35 (23.97) 0.81
Data are presented as number (percentage) of patients unless otherwise indicated.
Abbreviations: PCAD, premature coronary artery disease; others, see FIGURE 1
Table 3 Critical time intervals for reperfusion in the study patients with acute ST-segment elevation 
myocardial infarction during and before the coronavirus disease 2019 pandemic
Time interval, min During the COVID-19 outbreak 
(n = 178)
Before the COVID-19 outbreak 
(n = 146)
P value
Symptom onset to FMC 365.5 (144.75‒928.75) 363 (135.75‒930) 0.84
FMC to STEMI diagnosis 5 (5‒6) 5 (5‒10.25) 0.16
STEMI diagnosis to wire 
crossing
49.5 (35‒78.5) 50 (30.75‒85) 0.95
FMC to wire crossing 61 (42‒94.25) 67.5 (44.5‒134.25) 0.12
Data are presented as median (interquartile range).
Abbreviations: FMC, first medical contact; others, see FIGURE 1
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in the proximal part of the right coronary ar-
tery with good distal run-off. Successful PPCI 
of the left anterior descending artery was per-
formed, and the catheterization laboratory per-
sonnel wore full PPE during the procedure. Coro-
navirus disease 2019 was confirmed by spiral 
chest CT (FIGURE 2) and rRT-PCR nucleic acid testing 
on the day of admission. Supportive care includ-
ing ventilation and routine empiric treatment 
(hydroxychloroquine and lopinavir / ritonavir) 
was started. On the day following the procedure, 
the patient complained of dyspnea. Echocardiog-
raphy was immediately performed; left ventricu-
lar ejection fraction was 40% and no significant 
valvular disease or pericardial effusion were not-
ed. The patient’s oxygen saturation decreased to 
93%. However, his condition rapidly deteriorat-
ed and ventricular fibrillation occurred. Unfor-
tunately, cardiopulmonary resuscitation was un-
successful. Long QT intervals were not detected 
during the patient’s hospitalization. The creati-
nine level was 265.2 μmol/l, and electrolyte lev-
els were within the reference range. Severe hy-
poxia and acute respiratory disease in the con-
text of COVID-19 may be the causes of his death.
dIscussIon Our study demonstrated that 
the critical times for reperfusion in patients with 
STEMI undergoing PPCI (except the time from 
symptom onset to FMC) did not increase during 
the COVID-19 outbreak. Also, a trend towards 
shorter FMC-to-wire crossing time and its subin-
tervals was observed. Moreover, the outcomes of 
patients in terms of the 70-day occurrence of mor-
tality and nonfatal MACEs during the COVID-19 
outbreak did not differ from those in the cor-
responding time period in 2019. Considering 
the vast dimensions of the COVID-19 pandem-
ic, the impact of the disease on emergency man-
agement such as in acute MI is largely obscure.
Our findings regarding STEMI-related time 
components are in contrast to a recent study by 
Tam et al.4 The authors compared STEMI-related 
onset to FMC and from STEMI diagnosis to suc-
cessful wire crossing were 149 minutes and 30 
minutes, respectively. His coronary angiogra-
phy showed left anterior descending artery oc-
clusion at the mid part, normal diagonal arter-
ies, a normal left circumflex artery, 60% stenosis 
in the obtuse marginal artery, and 60% stenosis 
Table 4 Major adverse cardiac events at 70 days in the study patients with ST-segment elevation myocardial 
infarction who underwent primary coronary angioplasty before and during the coronavirus disease 2019 outbreak
MACE During the COVID-19 
outbreak (n = 178)
Before the COVID-19 
outbreak (n = 146)
P value
All-cause mortality 8 (4.49) 4 (2.73) 0.4
Repeated revascularization PCI 0 0 0.8
CABG 0 1 (0.68)
Nonfatal myocardial infarction 1 (0.56) 1 (0.68)
Cerebrovascular accidents 0 0
Rehospitalization 2 (1.12) 1 (0.68)
Data are presented as number (percentage) of patients.
Abbreviations: CABG, coronary artery bypass grafting; MACE, major adverse cardiac event; others, see FIGURE 1
Figure 2  Spiral chest computed tomography findings in a patient with confirmed coronavirus 
disease 2019 who died during hospitalization: ground-glass opacities suggestive of coronavirus 
disease 2019 in upper (a) and middle lung lobes (B)
a
B
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be ineffective but also routine cardiac catheter-
ization after fibrinolytic therapy may be associ-
ated with unfavorable outcomes, possibly due to 
increasing the risk of bleeding. Moreover, the ef-
ficacy of thrombolytic therapy for the treatment 
of systemic microthrombus formation associat-
ed with COVID-19 has not been proven yet.12,13 
In addition, total ischemic time prolongation is 
mostly attributable to the prehospital pathway 
(time from symptom onset to FMC), which is not 
affected by the reperfusion method.13
According to the ESC guidance for the diagno-
sis and management of cardiovascular diseases 
during the COVID-19 pandemic,14 if the STEMI 
diagnosis-to-wire crossing time frame is feasible 
within up to 120 minutes and the implementa-
tion of the approved COVID-19–dedicated pro-
tocol for patients and healthcare providers is ac-
cessible, PPCI remains the reperfusion method 
of choice. As shown in TAblE 3, the median time 
from STEMI diagnosis to wire crossing in our 
study was 49.5 minutes during the pandemic.
In this study, we demonstrated that the out-
comes of patients undergoing PPCI during the 
COVID-19 outbreak were the same as in the past. 
Meanwhile, using PPE, none of the catheteriza-
tion laboratory personnel members was infected 
despite performing PPCI in 21 patients with chest 
CT scans suggestive of COVID-19 and 7 patients 
with COVID-19 confirmed by a rRT-PCR test.
To conclude, if full PPE can be provided for 
the PPCI team, using the THC protocol for 
the management of patients with STEMI (FIGURE 1) 
might be a more efficient, practical, and evi-
dence-based approach compared with recom-
mendations to use thrombolytic therapy in pa-
tients with suspected or confirmed COVID-19. 
However, further studies of larger patient sam-
ples and with longer follow-up are needed to 
determine a standard protocol for the man-
agement of patients with acute STEMI during 
the COVID-19 pandemic.
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time components between 7 patients with STEMI 
who underwent PPCI within 15 days during 
the COVID-19 outbreak and 108 patients in 
a similar condition in the preceding year and ob-
served the prolongation of all time intervals dur-
ing the pandemic, especially the time from symp-
tom onset to FMC. Tam et al4 stated that those 
differences were related to patients’ unwilling-
ness to go to the hospital during the COVID-19 
outbreak and the time needed to implement in-
fection prevention protocols. In our study, we 
also observed a prolonged time interval from 
symptom onset to FMC. This finding may be re-
lated to patients’ disinclination to present to 
the emergency department during the pandemic. 
However, it seems that a lower number of elec-
tive invasive procedures during the COVID-19 
outbreak resulted in a shorter waiting time for 
the preparation of routinely occupied catheteriza-
tion laboratories and reduced staff workload, sub-
sequently showing improved performance. This 
was observed even though infection control pro-
tocols and PPE were routinely used in all patients.
Concerns regarding the spread of the disease 
prompted some recommendations and adapta-
tions in the standard management of patients 
with STEMI. A Chinese protocol11 suggested fast 
nucleic acid testing to detect suspected or con-
firmed cases of infection prior to deciding about 
the reperfusion strategy. Thrombolytic thera-
py was recommended in patients with suspect-
ed or confirmed COVID-19 with mild or mod-
erate pneumonia who present to the emergen-
cy department within 12 hours from symptom 
onset. However, this approach has been chal-
lenged in other communities, eg, in the United 
States where PPCI is a routine revascularization 
method. Additionally, rapid nucleic acid testing 
is not easily available for all patients. The Ameri-
can College of Cardiology’s Interventional Coun-
cil and the Society of Cardiovascular Angiog-
raphy and Interventions recommended fibri-
nolytic therapy as an option in relatively sta-
ble patients with STEMI and confirmed active 
COVID-19. The use of appropriate PPE is advised 
if PPCI is to be performed in those cases.5 An-
other study recommended a single-bolus admin-
istration of fibrinolytics as the preferred meth-
od in early presenting stable patients with lim-
ited infarct size, when time delays due to cath-
eterization laboratory staff preparation, lack of 
beds, scarce PPE, and considerable absence rates 
of the hospital personnel may increase the use 
of thrombolytic therapy.12 However, routine cor-
onary angiography and / or rescue angioplasty 
usually performed following thrombolytic ther-
apy negate the possible advantage of fibrinolysis 
with regard to limiting the staff exposure and 
PPE consumption.13 Furthermore, lytic therapy 
is challenging in patients with COVID-19–relat-
ed myopericarditis with symptoms mimicking 
STEMI, in whom not only reperfusion is likely to 
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